|
Nov 29
|
Is Alpine Immune Sciences (ALPN) Outperforming Other Medical Stocks This Year?
|
|
Nov 29
|
Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study
|
|
Nov 29
|
Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?
|
|
Nov 29
|
15 Most Socialist States In The US
|
|
Nov 28
|
UPDATE 1-Suspected fake Ozempic causes hypoglycemia in 11 in Lebanon
|
|
Nov 28
|
Lilly's Weight-Loss Drug Wallops Novo's In Head-To-Head Study; Novo Stock Dives
|
|
Nov 9
|
The Weight-Loss Drug Showdown Is Coming. Why Eli Lilly’s Treatment Costs Less Than Wegovy.
|
|
Nov 9
|
AstraZeneca enters weight-loss market with oral GLP-1 drug
|
|
Nov 9
|
AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost.
|
|
Nov 9
|
Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
|
|
Nov 9
|
People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions
|
|
Nov 9
|
Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug—and it’s nearly $300 cheaper than Wegovy
|
|
Nov 9
|
Weight loss drugs transforming healthcare, may help with addiction -Reuters Events
|
|
Nov 9
|
Approval for Eli Lilly obesity drug sets up rival to Wegovy
|
|
Nov 8
|
FDA approves Eli Lilly's Mounjaro for weight loss
|
|
Nov 8
|
Eli Lilly Stock Jumps on Obesity Drug’s FDA Approval
|
|
Nov 8
|
Eli Lilly Wins FDA Nod for Obesity Drug That Rivals Wegovy, Ozempic
|
|
Nov 8
|
Wegovy rival Zepbound wins approval amid weight-loss jab gold rush
|
|
Nov 8
|
Novo Nordisk to discontinue Levemir insulin in U.S. market
|
|
Nov 8
|
Data on Pfizer’s New Weight Loss Pill Is Coming. Why it’s Crucial for the Stock.
|